Aspirin may no longer be effective as cardiovascular treatment

December 09, 2019

A new paper in Family Practice, published by Oxford University Press, found that the widespread use of statins and cancer screening technology may have altered the benefits of aspirin use. Researchers concluded that aspirin no longer provides a net benefit as primary prevention for cardiovascular disease and cancer.

Nearly half of adults 70 years and older have reported taking aspirin daily even if they don't have a history of heart disease or stroke. Overall, an estimated 40% of adults in the United States take aspirin for primary prevention of cardiovascular diseases, making it one of our most commonly used medications

Researchers conducted the first review of aspirin's role in cardiovascular prevention 30 years ago, reporting a reduction in risk for both fatal and non-fatal heart attacks. Subsequent reports also found a reduction in cancer deaths for patients taking aspirin for five or more years, but no reduction in cardiovascular related deaths or strokes, and consistently displayed a significant risk of major bleeding complications.

Most of these aspirin trials were set in Europe and the United States and recruited patients prior to 2000. Since then, cholesterol-lowering drugs have gone into widespread use, accompanied by better management of hypertension, less tobacco use, and widespread adoption of colorectal cancer screening.

Researchers compared these older studies with four recent large scale trials of aspirin. Broadly, participants in the newer trials resembled the contemporary population that would use aspirin for primary prevention. In comparison, they were older, somewhat less likely to smoke, and more likely to have type 2 diabetes than patients in the older trials.

Like older studies, the recent trials of aspirin for primary prevention found no mortality benefit and a significant increase in the risk of major haemorrhages. However, they failed to find evidence for the two important benefits of aspirin: a reduction in the risk of cancer deaths and a reduced risk of non-fatal heart attacks. For every 1000 patients who took aspirin for five years there were four fewer major cardiovascular events but 7 more episodes of major haemorrhage and no change to overall cardiovascular mortality.

With the widespread use of statins and population wide cancer screenings today, aspirin may no longer reduce the overall risk of cancer death or heart attack when given as primary prevention.

"The good news is that the incidence of cardiovascular disease and colorectal cancer are decreasing due to better control of risk factors and screening, but that also seems to reduce the potential benefit of aspirin."
-end-
The paper "A comparison of contemporary versus older studies of aspirin for primary prevention" is available at: https://academic.oup.com/fampra/advance-article/doi/10.1093/fampra/cmz080/5637484?searchresult=1

Direct correspondence to:

Mark H. Ebell
Professor of Epidemiology and Biostatistics
College of Public Health, University of Georgia
125 Miller Hall
UGA Health Sciences Campus
Athens, GA
30602
ebell@uga.edu

To request a copy of the study, please contact:

Timothy Thomas
timothy.thomas@oup.com

Sharing on social media? Find Oxford Journals online at @OxfordJournals

DOI: 10.1093/fampra/cmz080

Please acknowledge Family Practice as a source in any articles.

Funding:

This work was supported in part by a 2019 Fulbright Teaching/Research Award to Dr. Ebell, and the HRB Centre for Primary Care Research grant (HRC/2014/01) for Dr. Moriarty.

Oxford University Press USA

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.